65 related articles for article (PubMed ID: 23397419)
1. Lipid efflux mediated by alkylphospholipids in HepG2 cells.
Ríos-Marco P; Segovia JL; Jiménez-López JM; Marco C; Carrasco MP
Cell Biochem Biophys; 2013 Jul; 66(3):737-46. PubMed ID: 23397419
[TBL] [Abstract][Full Text] [Related]
2. Antitumoral alkylphospholipids induce cholesterol efflux from the plasma membrane in HepG2 cells.
Ríos-Marco P; Jiménez-López JM; Marco C; Segovia JL; Carrasco MP
J Pharmacol Exp Ther; 2011 Mar; 336(3):866-73. PubMed ID: 21148684
[TBL] [Abstract][Full Text] [Related]
3. Antitumoral alkylphospholipids alter cell lipid metabolism.
Marco C; Ríos-Marco P; Jiménez-López JM; Segovia JL; Carrasco MP
Anticancer Agents Med Chem; 2014 May; 14(4):545-58. PubMed ID: 24628237
[TBL] [Abstract][Full Text] [Related]
4. Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells.
Marco C; Jiménez-López JM; Ríos-Marco P; Segovia JL; Carrasco MP
Int J Biochem Cell Biol; 2009 Jun; 41(6):1296-303. PubMed ID: 19084611
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of antitumour alkylphospholipids on cholesterol transport and metabolism.
Ríos-Marco P; Marco C; Cueto FJ; Carrasco MP; Jiménez-López JM
Exp Cell Res; 2016 Jan; 340(1):81-90. PubMed ID: 26712518
[TBL] [Abstract][Full Text] [Related]
6. Alkylphospholipids: An update on molecular mechanisms and clinical relevance.
Ríos-Marco P; Marco C; Gálvez X; Jiménez-López JM; Carrasco MP
Biochim Biophys Acta Biomembr; 2017 Sep; 1859(9 Pt B):1657-1667. PubMed ID: 28238819
[TBL] [Abstract][Full Text] [Related]
7. Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues.
Carrasco MP; Jiménez-López JM; Ríos-Marco P; Segovia JL; Marco C
Br J Pharmacol; 2010 May; 160(2):355-66. PubMed ID: 20423345
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.
Jiménez-López JM; Ríos-Marco P; Marco C; Segovia JL; Carrasco MP
Lipids Health Dis; 2010 Mar; 9():33. PubMed ID: 20338039
[TBL] [Abstract][Full Text] [Related]
9. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.
van der Luit AH; Vink SR; Klarenbeek JB; Perrissoud D; Solary E; Verheij M; van Blitterswijk WJ
Mol Cancer Ther; 2007 Aug; 6(8):2337-45. PubMed ID: 17699729
[TBL] [Abstract][Full Text] [Related]
10. Alkylphospholipids deregulate cholesterol metabolism and induce cell-cycle arrest and autophagy in U-87 MG glioblastoma cells.
Ríos-Marco P; Martín-Fernández M; Soria-Bretones I; Ríos A; Carrasco MP; Marco C
Biochim Biophys Acta; 2013 Aug; 1831(8):1322-34. PubMed ID: 23707264
[TBL] [Abstract][Full Text] [Related]
11. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Vink SR; van der Luit AH; Klarenbeek JB; Verheij M; van Blitterswijk WJ
Biochem Pharmacol; 2007 Nov; 74(10):1456-65. PubMed ID: 17803969
[TBL] [Abstract][Full Text] [Related]
12. Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress.
Lluis JM; Colell A; García-Ruiz C; Kaplowitz N; Fernández-Checa JC
Gastroenterology; 2003 Mar; 124(3):708-24. PubMed ID: 12612910
[TBL] [Abstract][Full Text] [Related]
13. Mevalonate inhibits acid sphingomyelinase activity, increases sphingomyelin levels and inhibits cell proliferation of HepG2 and Caco-2 cells.
Chen Y; Xu SC; Duan RD
Lipids Health Dis; 2015 Oct; 14():130. PubMed ID: 26493087
[TBL] [Abstract][Full Text] [Related]
14. Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells.
Carrasco MP; Jiménez-López JM; Segovia JL; Marco C
FEBS J; 2008 Apr; 275(8):1675-86. PubMed ID: 18312412
[TBL] [Abstract][Full Text] [Related]
15. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
[TBL] [Abstract][Full Text] [Related]
16. Efflux of cholesterol from different cellular pools.
Haynes MP; Phillips MC; Rothblat GH
Biochemistry; 2000 Apr; 39(15):4508-17. PubMed ID: 10758000
[TBL] [Abstract][Full Text] [Related]
17. Sterol carrier protein-2 selectively alters lipid composition and cholesterol dynamics of caveolae/lipid raft vs nonraft domains in L-cell fibroblast plasma membranes.
Atshaves BP; Gallegos AM; McIntosh AL; Kier AB; Schroeder F
Biochemistry; 2003 Dec; 42(49):14583-98. PubMed ID: 14661971
[TBL] [Abstract][Full Text] [Related]
18. Alkylphospholipids reversibly open epithelial tight junctions.
Leroy A; de Bruyne GK; Oomen LC; Mareel MM
Anticancer Res; 2003; 23(1A):27-32. PubMed ID: 12680191
[TBL] [Abstract][Full Text] [Related]
19. Hexadecylphosphocholine disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells.
Jiménez-López JM; Carrasco MP; Marco C; Segovia JL
Biochem Pharmacol; 2006 Apr; 71(8):1114-21. PubMed ID: 16466701
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel anionic phospholipid binding domains in neutral sphingomyelinase 2 with selective binding preference.
Wu BX; Clarke CJ; Matmati N; Montefusco D; Bartke N; Hannun YA
J Biol Chem; 2011 Jun; 286(25):22362-71. PubMed ID: 21550973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
